Vanguard Group’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $35.1M | Buy |
2,631,648
+65,327
| +3% | +$872K | ﹤0.01% | 2289 |
|
|
2025
Q1 | $26.2M | Buy |
2,566,321
+609,212
| +31% | +$6.21M | ﹤0.01% | 2384 |
|
|
2024
Q4 | $31M | Buy |
1,957,109
+100,691
| +5% | +$1.59M | ﹤0.01% | 2374 |
|
|
2024
Q3 | $108M | Buy |
1,856,418
+99,298
| +6% | +$5.77M | ﹤0.01% | 1839 |
|
|
2024
Q2 | $80.3M | Buy |
1,757,120
+211,362
| +14% | +$9.66M | ﹤0.01% | 1941 |
|
|
2024
Q1 | $102M | Buy |
1,545,758
+113,563
| +8% | +$7.52M | ﹤0.01% | 1859 |
|
|
2023
Q4 | $56.9M | Buy |
1,432,195
+25,764
| +2% | +$1.02M | ﹤0.01% | 2129 |
|
|
2023
Q3 | $44.8M | Buy |
1,406,431
+222,652
| +19% | +$7.1M | ﹤0.01% | 2182 |
|
|
2023
Q2 | $47.6M | Buy |
1,183,779
+135,717
| +13% | +$5.45M | ﹤0.01% | 2206 |
|
|
2023
Q1 | $44.8M | Buy |
1,048,062
+2,742
| +0.3% | +$117K | ﹤0.01% | 2221 |
|
|
2022
Q4 | $50.2M | Buy |
1,045,320
+138,746
| +15% | +$6.66M | ﹤0.01% | 2185 |
|
|
2022
Q3 | $34.1M | Buy |
906,574
+134,956
| +17% | +$5.08M | ﹤0.01% | 2374 |
|
|
2022
Q2 | $21.3M | Buy |
771,618
+35,025
| +5% | +$968K | ﹤0.01% | 2608 |
|
|
2022
Q1 | $40.1M | Buy |
736,593
+2,873
| +0.4% | +$156K | ﹤0.01% | 2413 |
|
|
2021
Q4 | $42.9M | Buy |
733,720
+23,959
| +3% | +$1.4M | ﹤0.01% | 2438 |
|
|
2021
Q3 | $28.1M | Buy |
709,761
+41,558
| +6% | +$1.64M | ﹤0.01% | 2665 |
|
|
2021
Q2 | $28.4M | Buy |
668,203
+65,557
| +11% | +$2.78M | ﹤0.01% | 2659 |
|
|
2021
Q1 | $37.1M | Buy |
602,646
+10,391
| +2% | +$640K | ﹤0.01% | 2468 |
|
|
2020
Q4 | $41.8M | Buy |
592,255
+293,324
| +98% | +$20.7M | ﹤0.01% | 2294 |
|
|
2020
Q3 | $11.5M | Sell |
298,931
-13,476
| -4% | -$520K | ﹤0.01% | 2721 |
|
|
2020
Q2 | $11.7M | Buy |
+312,407
| New | +$11.7M | ﹤0.01% | 2688 |
|